JP2022541514A5 - - Google Patents
Info
- Publication number
- JP2022541514A5 JP2022541514A5 JP2022502902A JP2022502902A JP2022541514A5 JP 2022541514 A5 JP2022541514 A5 JP 2022541514A5 JP 2022502902 A JP2022502902 A JP 2022502902A JP 2022502902 A JP2022502902 A JP 2022502902A JP 2022541514 A5 JP2022541514 A5 JP 2022541514A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875409P | 2019-07-17 | 2019-07-17 | |
| US62/875,409 | 2019-07-17 | ||
| PCT/IB2020/000668 WO2021009567A1 (en) | 2019-07-17 | 2020-07-16 | Nlrp3 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541514A JP2022541514A (ja) | 2022-09-26 |
| JP2022541514A5 true JP2022541514A5 (enExample) | 2023-07-06 |
| JP7595642B2 JP7595642B2 (ja) | 2024-12-06 |
Family
ID=72659815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502902A Active JP7595642B2 (ja) | 2019-07-17 | 2020-07-16 | Ｎｌｒｐ３モジュレーター |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12351564B2 (enExample) |
| EP (1) | EP3999179A1 (enExample) |
| JP (1) | JP7595642B2 (enExample) |
| KR (1) | KR102852270B1 (enExample) |
| CN (1) | CN114555569B (enExample) |
| AU (1) | AU2020314186B2 (enExample) |
| BR (1) | BR112022000855A2 (enExample) |
| CA (1) | CA3147571A1 (enExample) |
| IL (1) | IL289890B2 (enExample) |
| MX (1) | MX2022000712A (enExample) |
| WO (1) | WO2021009567A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| JP7595642B2 (ja) | 2019-07-17 | 2024-12-06 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| KR20220154165A (ko) | 2020-03-16 | 2022-11-21 | 조마젠 바이오사이언시즈 엘티디 | Nlrp3 조절제 |
| JP7825294B2 (ja) * | 2021-02-10 | 2026-03-06 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| EP4362946A4 (en) * | 2021-06-29 | 2025-05-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| KR102877100B1 (ko) | 2022-05-30 | 2025-10-24 | 주식회사 엘지에너지솔루션 | 배터리 진단 장치 및 방법 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2026054623A1 (ko) * | 2024-09-09 | 2026-03-12 | (주) 업테라 | 신규 nlrp3 억제제 화합물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102727059B1 (ko) | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| CN109071454B (zh) | 2016-02-16 | 2023-02-17 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| US11597706B2 (en) | 2016-04-18 | 2023-03-07 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| CA3047336A1 (en) * | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
| US11465992B2 (en) * | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11542255B2 (en) * | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MX2020001776A (es) * | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| JP2020531448A (ja) * | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| EP3697758B1 (en) * | 2017-10-17 | 2022-07-06 | Novartis AG | Sulphonamides and compositions thereof for treating conditions associated with nlrp activity |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CN113056451A (zh) | 2018-10-24 | 2021-06-29 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| JP7595642B2 (ja) | 2019-07-17 | 2024-12-06 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| CL2022002490A1 (es) | 2020-03-16 | 2023-05-05 | Novartis Ag | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead |
| KR20220154165A (ko) | 2020-03-16 | 2022-11-21 | 조마젠 바이오사이언시즈 엘티디 | Nlrp3 조절제 |
| UY39129A (es) | 2020-03-16 | 2021-10-29 | Novartis Ag | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead |
-
2020
- 2020-07-16 JP JP2022502902A patent/JP7595642B2/ja active Active
- 2020-07-16 US US17/627,084 patent/US12351564B2/en active Active
- 2020-07-16 KR KR1020227005291A patent/KR102852270B1/ko active Active
- 2020-07-16 MX MX2022000712A patent/MX2022000712A/es unknown
- 2020-07-16 CA CA3147571A patent/CA3147571A1/en active Pending
- 2020-07-16 AU AU2020314186A patent/AU2020314186B2/en active Active
- 2020-07-16 WO PCT/IB2020/000668 patent/WO2021009567A1/en not_active Ceased
- 2020-07-16 IL IL289890A patent/IL289890B2/en unknown
- 2020-07-16 EP EP20781062.3A patent/EP3999179A1/en active Pending
- 2020-07-16 CN CN202080064393.6A patent/CN114555569B/zh active Active
- 2020-07-16 BR BR112022000855A patent/BR112022000855A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022541514A5 (enExample) | ||
| JP2022541254A5 (enExample) | ||
| JP2024529839A5 (enExample) | ||
| JP2025509697A5 (enExample) | ||
| JP2020514333A5 (enExample) | ||
| JP2023538408A5 (enExample) | ||
| JP6907173B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP7145931B2 (ja) | 化合物の結晶多形、その製造方法及び用途 | |
| JP2020514334A5 (enExample) | ||
| HRP20241656T1 (hr) | Derivat nitrila koji djeluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba | |
| JP4206382B2 (ja) | 置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター | |
| JP2017512186A5 (enExample) | ||
| JP2023518044A5 (enExample) | ||
| JP2010539083A5 (enExample) | ||
| JP2021500403A5 (enExample) | ||
| CA2475712A1 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| JP2008543860A5 (enExample) | ||
| ME02188B (me) | Mali molekuli koji sadrže boron kao antiinflamatorni agensi | |
| JP2011513367A5 (enExample) | ||
| JP2023504415A5 (enExample) | ||
| JP2013525448A5 (enExample) | ||
| JP2023076632A5 (enExample) | ||
| JP2015508068A5 (enExample) | ||
| JP2021533206A5 (enExample) |